The impact of an ‘evergreening’ strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands

Author:

Kirshner Ghyli,Makai PeterORCID,Brouns Chiara,Timmers Lonneke,Kemp RonORCID

Abstract

AbstractIn this paper, we explore dynamic market share and public healthcare costs of trastuzumab’s evergreening (subcutaneous) variant during introduction of trastuzumab’s competitive biosimilar variants in the Netherlands. We used a time series design to assess dynamic market share of trastuzumab’s evergreening variant after introducing trastuzumab’s biosimilar variants, focusing on the number of treatments and patients. The public healthcare costs of this evergreening strategy were estimated using administrative claims data. Our results show that the original trastuzumab was completely replaced by the subcutaneous and biosimilar variants. The uptake of the subcutaneous form peaked at 50% market share but after the introduction of biosimilars progressively reduced to a market share of 20%, resulting in a more competitive market structure. The public healthcare costs for trastuzumab significantly decreased after the introduction of the biosimilars. After the introduction of the biosimilars, a substantial price drop is visible, with the subcutaneous version, still under patent, also falling sharply in price but less strongly than the iv/biosimilar version. As the costs are publicly funded, we recommend a more explicit societal debate to consider if the potential benefits of subcutaneous Herceptin® (and other similar medicines) are worth the additional costs, and at which price it should be reimbursed as the part of the benefit package.

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Reference44 articles.

1. NZa (Dutch Healthcare Authority). Monitor Medisch specialistische zorg 2020 (in Dutch). NZa, Utrecht, the Netherlands (2020)

2. Dwivedi, G., Hallihosur, S., Rangan, L.: Evergreening: a deceptive device in patent rights. Technol. Soc. 32(4), 324–330 (2010)

3. Blackstone, E.A., Joseph, P.F.: The economics of biosimilars. Am. Health Drug Benefits 6(8), 469 (2013)

4. IQVIA. Protection Expiry and Journey into the Market. IQVIA, Durham, NC (2022)

5. Dutta, B., Huys, I., Vulto, A.G., Simoens, S.: Identifying key benefits in European Off-patent biologics and biosimilar markets: it is not only about price! BioDrugs: Clin. Immunother. Biopharm. Gene Ther. 34(2), 159–170 (2020)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3